STUDIO CLINICO TRA CARBAMAZEPINA A RILASCIO CONTROLLATO (CR) E CONVENZIONALE IN ETA PEDIATRICA: DISEGNO IN DOPPIO CIECO, ENTRO PAZIENTE

Translated title of the contribution: Controlled-release CBZ vs conventional: A double-blind, cross-over study in children

T. Granata, D. Battino, S. Binelli, A. Moise, G. C. Monza

Research output: Contribution to journalArticlepeer-review

Abstract

Efficacy and tolerability of a new controlled-release (CR) formulation of carbamazepine (CBZ) (Tegretol 200 mg CR), were assessed in a double-blind, two-period cross-over trial, carried out in 18 children with partial epilepsy (12 males, 6 females; mean age: 12.5 years, range 7-16 years). Before entering the study patients had been taking conventional CBZ on monotherapy (n=11) or in combination with clobazam (n=7), without complete seizure control (n=14), or with intermittent side-effects (n= 1) or with both seizures and side-effects (n=3). The mean daily CBZ dose has been significantly increased (p

Translated title of the contributionControlled-release CBZ vs conventional: A double-blind, cross-over study in children
Original languageItalian
Pages (from-to)367-368
Number of pages2
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number70-71
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Controlled-release CBZ vs conventional: A double-blind, cross-over study in children'. Together they form a unique fingerprint.

Cite this